

PERFLUOROOCTANOIC ACID (PFOA) AND PERFLUOROOCTANESULFONIC ACID (PFOS)

VOLUME 135

This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met in Lyon, France, 7–14 November 2023

LYON, FRANCE - 2025

IARC MONOGRAPHS
ON THE IDENTIFICATION
OF CARCINOGENIC HAZARDS
TO HUMANS

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background	9
2. Objective and scope	10
3. Selection of agents for review	11
4. The Working Group and other meeting participants	11
5. Working procedures	13
6. Overview of the scientific review and evaluation process	14
7. Responsibilities of the Working Group	16
B. SCIENTIFIC REVIEW AND EVALUATION	17
1. Exposure characterization	17
2. Studies of cancer in humans	20
3. Studies of cancer in experimental animals	25
4. Mechanistic evidence	28
5. Summary of data reported	31
6. Evaluation and rationale	32
References	37
GENERAL REMARKS	41
1. EXPOSURE CHARACTERIZATION	49
1.1 Identification of the agent	49
1.2 Production and uses	55
1.3 Detection and quantification	57
1.4 Occurrence and exposure	68
1.5 Regulations and guidelines	112
1.6 Quality of exposure assessment in key epidemiological studies of cancer and mechanistic studies in humans	116
References	131

2. CANCER IN HUMANS	157
2.1 Cohort descriptions	158
2.2 Cancers of the urinary tract	213
2.3 Cancers of the male genital tract	252
2.4 Cancers of the breast and thyroid gland	280
2.5 Cancers of the digestive tract	347
2.6 Cancers of the brain and lymphatic and haematopoietic tissue	358
2.7 Cancer of all sites combined	366
2.8 Evidence synthesis for cancer in humans	370
References	390
3. CANCER IN EXPERIMENTAL ANIMALS	397
3.1 Perfluorooctanoic acid (PFOA)	397
3.2 Perfluorooctanesulfonic acid (PFOS)	425
3.3 Evidence synthesis for cancer in experimental animals	435
References	438
4. MECHANISTIC EVIDENCE	441
4.1 Absorption, distribution, metabolism, and excretion	441
4.2 Evidence relevant to key characteristics of carcinogens	454
4.3 Evaluation of high-throughput in vitro screening data	658
References	662
5. SUMMARY OF DATA REPORTED	705
5.1 Exposure characterization	705
5.2 Cancer in humans	706
5.3 Cancer in experimental animals	710
5.4 Mechanistic evidence	711
6. EVALUATION AND RATIONALE	717
6.1 Cancer in humans	717
6.2 Cancer in experimental animals	717
6.3 Mechanistic evidence	717
6.4 Overall evaluation	717
6.5 Rationale	717
LIST OF ABBREVIATIONS	719
ANNEX 1. Supplementary material for Section 1, Exposure Characterization	727
ANNEX 2. Actions and regulations for the elimination of PFAS worldwide	729
ANNEX 3. Supplementary analyses used in reviewing evidence on cancer in humans	733
ANNEX 4. Supplementary material for Section 2, Cancer in Humans	747
ANNEX 5. Supplementary material for Sections 4.1 and 4.2, Mechanistic Evidence	749

ANNEX 6. Supplementary material for Section 4.3, Mechanistic Evidence	751
SUMMARY OF FINAL EVALUATIONS.....	753